Neurona Therapeutics’ NRTX-1001 Shows Continued Seizure Reduction in Clinical Trial for Mesial Temporal Lobe Epilepsy (MTLE)
Neurona Therapeutics has announced updated clinical data from its ongoing Phase I/II clinical trial of NRTX-1001, a regenerative cell therapy for the treatment of drug-resistant mesial temporal lobe epilepsy (MTLE). The data reveals a significant reduction in seizure frequency, with more than 90% reduction observed in the first two patients at five- and nine-months post-treatment. … Read more